Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
reALiSe: ARGX-119 in adults with amyotrophic lateral sclerosis
NL-OMON59440Phase 2Completed
- Sponsor
- argenx
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of adimanebart in amyotrophic lateral sclerosis (ALS), sponsored by argenx. Primary endpoints: Adverse events and Clinical safety assessments. Started Oct 2024; status: completed.
02
Drugs
adimanebart
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON59440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59440.